{"entity":{"id":"nct00066703","kind":"trial","name":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","aka":["TEXT"],"tldr":"A phase 3 trial of Tamoxifen and Triptorelin in Breast cancer, run by ETOP IBCSG Partners Foundation, completed.","summary":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer is a phase 3 interventional study registered as NCT00066703 by ETOP IBCSG Partners Foundation, with 2672 participants recorded, started 2003-11-03 and reaching its primary completion in 2011-03-11. Interventions recorded: exemestane, tamoxifen, triptorelin. Conditions recorded: Breast Cancer.\n\nLinked to the drug Triptorelin because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00066703","url":"https://clinicaltrials.gov/study/NCT00066703"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["tamoxifen","triptorelin"],"companies":["etop-ibcsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00066703","phase":"3","setting":"A Phase III Trial Evaluating The Role Of Exemestane Plus GnRH Analogue As Adjuvant Therapy For Premenopausal Women With Endocrine Responsive Breast Cancer","sponsor":"ETOP IBCSG Partners Foundation","started":"2003-11-03","startedType":"actual","yearReported":2016,"enrolled":2672,"enrolledBasis":"registry","outcomes":[{"endpoint":"Disease-free Survival","primary":true,"unit":"%","arms":[{"name":"T+OFS","n":1328,"value":87.3,"note":"95% CI 85.7 to 88.7; Figures from the ClinicalTrials.gov results section (first posted 2016-04-05), not from a publication"},{"name":"E+OFS","n":1332,"value":91.1,"note":"95% CI 89.7 to 92.3"}],"hr":0.717,"ci":[0.602,0.855],"p":".0002","source":"https://clinicaltrials.gov/study/NCT00066703?tab=results"},{"endpoint":"Overall Survival","unit":"%","arms":[{"name":"T+OFS","n":1328,"value":93.3,"note":"95% CI 92.1 to 94.3; Figures from the ClinicalTrials.gov results section (first posted 2016-04-05), not from a publication"},{"name":"E+OFS","n":1332,"value":93.4,"note":"95% CI 92.2 to 94.4"}],"hr":0.98,"ci":[0.79,1.22],"p":"0.84","source":"https://clinicaltrials.gov/study/NCT00066703?tab=results"}]},"route":"/trials/nct00066703/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"tamoxifen","kind":"drug","name":"Tamoxifen","route":"/drugs/tamoxifen/"},{"id":"triptorelin","kind":"drug","name":"Triptorelin","route":"/drugs/triptorelin/"}],"company":[{"id":"etop-ibcsg","kind":"company","name":"ETOP IBCSG Partners Foundation","route":"/companies/etop-ibcsg/"}]}}